Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Investment opportunities in atopic dermatitis may drive innovation
The atopic dermatitis (AD) market is projected to reach $16.7bn by 2030, driven by global AD prevalence and clinical trial advancements. Standard treatments offer temporary relief, prompting the need for more effective therapies. Innovative treatments like BTLA and OX40 inhibitors, bacterial therapies, and NTMs show promise. Pharmaceutical companies should invest in R&D, form alliances, and adopt patient-focused strategies to capitalize on market growth.
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche's fenebrutinib achieved a mid-stage win in RMS, showing near-total elimination of disease activity, while Sanofi's tolebrutinib had mixed results, missing primary endpoints in two Phase III studies but succeeding in a third, delaying disability progression in progressive MS. Both drugs face safety concerns, particularly liver injury, which will be a key focus at upcoming presentations. Despite mixed results, tolebrutinib is expected to generate $2.6 billion in sales by 2030, while fenebrutinib is projected to reach $810 million.
GSK antibody drug reduces COPD attacks in trial
GSK's Nucala succeeded in a Phase 3 study for COPD patients with chronic bronchitis/emphysema, significantly reducing exacerbations. This follows a 2018 FDA rejection for lack of data. Nucala targets interleukin-5 and is already approved for severe asthma. GSK will discuss the new data with regulators and present it at a future medical meeting.
GSK Builds Nucala's COPD Case With Phase III Win
GSK announced positive Phase III MATINEE trial results for Nucala, showing a reduction in COPD exacerbations. Nucala, a monoclonal antibody targeting IL-5, is currently approved for severe asthma and other conditions but not COPD. GSK plans to present full trial findings and share results with health authorities. The COPD market is anticipating potential approvals for Sanofi and Regeneron's Dupixent and Verona's Ohtuvayre.
Lykos CEO to Resign After FDA Rejection of MDMA Therapy, Layoffs
Lykos Therapeutics CEO Amy Emerson steps down, interim CEO Michael Mullette appointed. Emerson to remain as senior advisor. Lykos faces FDA rejection for MDMA therapy, plans resubmission. Company also names David Hough as CMO and lays off 75% of workforce.
GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction
M.J.D. has consulted, advised, and spoken for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, AstraZeneca, Zealand Pharma, Carmot/Roche, and Amgen. She has also received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen, Sanofi-Aventis, and Eli Lilly. J.G. has no competing interests.
GSK's asthma blockbuster Nucala secures win in COPD Phase III trial
GSK's asthma drug Nucala met primary endpoint in Phase III COPD trial, reducing exacerbations when added to inhaled therapy. GSK anticipates EU and Canada regulatory submission in 2025. Nucala, an IL-5 antagonist, generated £1.6bn in 2023 and is predicted to reach $2.35bn by 2026.
GSK Asthma Drug Shows Promise in Treating Chronic Lung Disease
GSK's Nucala showed significant reduction in COPD flare-ups in a trial, potentially expanding its use beyond asthma treatment.
Lykos CEO to depart after FDA rejection, layoffs
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
© Copyright 2025. All Rights Reserved by MedPath